215876-15-6

Upstream product

• 2746-25-0 p-Methoxybenzyl bromide 

Downstream Products

• 215876-19-0 [1-[6-(2-benzenesulfonyl-1,1-dimethyl-ethyl)-3,4-dihydro-2H-pyran-2-ylmethyl]-2-(4-methoxy-benzyloxy)-propoxy]-tert-butyl-dimethyl-silane 
• 215876-18-9 (7S,9R,10R)-1-Benzenesulfonyl-9-(tert-butyl-dimethyl-silanyloxy)-7-hydroxy-10-(4-methoxy-benzyloxy)-2,2-dimethyl-undecan-3-one 
• 215876-17-8 4-Nitro-benzoic acid (S)-7-benzenesulfonyl-1-[(2R,3R)-2-hydroxy-3-(4-methoxy-benzyloxy)-butyl]-6,6-dimethyl-5-oxo-heptyl ester 
• 247146-57-2 4-Nitro-benzoic acid (S)-7-benzenesulfonyl-1-[(2R,3R)-2-(tert-butyl-dimethyl-silanyloxy)-3-(4-methoxy-benzyloxy)-butyl]-6,6-dimethyl-5-oxo-heptyl ester 
• 247146-85-6 [(2S,4R,6R)-4-(tert-Butyl-dimethyl-silanyloxy)-6-((E)-3-{(S)-6-[(2R,3R)-2-(tert-butyl-dimethyl-silanyloxy)-3-(4-methoxy-benzyloxy)-butyl]-5,6-dihydro-4H-pyran-2-yl}-3-methyl-but-1-enyl)-tetrahydro-pyran-2-yl]-methanol 
• 215876-20-3 6-{3-[4-(tert-butyl-dimethyl-silanyloxy)-6-(tert-butyl-dimethyl-silanyloxymethyl)-tetrahydro-pyran-2-yl]-1,1-dimethyl-allyl}-2-[2-(tert-butyl-dimethyl-silanyloxy)-3-(4-methoxy-benzyloxy)-butyl]-3,4-dihydro-2H-pyran 
• 215876-21-4 trifluoro-methanesulfonic acid 4-(tert-butyl-dimethyl-silanyloxy)-6-(3-{6-[2-(tert-butyl-dimethyl-silanyloxy)-3-(4-methoxy-benzyloxy)-butyl]-5,6-dihydro-4H-pyran-2-yl}-3-methyl-but-1-enyl)-tetrahydro-pyran-2-ylmethyl ester 
• 247146-64-1 C₅₄H₉₂O₁₁SSi₃ 
• 215876-22-5 C₇₁H₁₁₅NO₁₂Si₃ 
• 215876-23-6 C₇₇H₁₂₉NO₁₂Si₄ 

Relevant academic research and scientific papers

Asymmetric synthesis of bryostatin 2

The potent bryostatin antitumor agents are currently in phase II clinical trials for the treatment of a variety of forms of cancer. Aldol reactions and directed reductions are among the essential steps for the formation of fragments A-C in the total synthesis of the title compound. Coupling of these fragments by sulfone-based olefination and alkylation reactions was followed by macrocyclization and introduction of the enoate moieties on rings B and C.